希西莫托甲状腺炎患者补充的临床疗效:系统性审查和元分析

Xiang-Qi Kong1, Gui-Ying Qiu2, Zhong-Bin Yang3

  • 1Department of Geriatrics, Shenzhen Longhua District Central Hospital, The Affiliated Central Hospital of Shenzhen Longhua District, Guangdong Medical University, Shenzhen, China.

Medicine
|June 19, 2023
PubMed
概括

补充剂在半年后显著降低了哈希莫托甲状腺炎患者的甲状腺抗体. 需要进一步的研究来评估长期健康影响和疾病进展.